Thalidomide: A new anticancer drug?

Expert Opinion on Investigational Drugs

Volumn 12, Issue 7, 2003, Pages 1211-1225

  Fanelli, Massimo ^a   Sarmiento, Roberta ^a   Gattuso, Domenico ^a   Carillio, Guido ^a   Capaccetti, Barbara ^a   Vacca, Angelo ^b   Roccaro, Aldo Maria ^b   Gasparini, Giampietro ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b Section of Internal Medicine and Clinical Oncology   (Italy)

Author keywords

Angiogenesis; Anticancer therapy; Biological treatment; Thalidomide

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CLARITHROMYCIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 1; INTERLEUKIN 2; IRINOTECAN; MELPHALAN; PACLITAXEL; PENTOXIFYLLINE; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; STEROID; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINBLASTINE;

AMYLOIDOSIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BRADYCARDIA; CACHEXIA; CANCER SURVIVAL; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; ENDOCRINE DISEASE; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSTIMULATION; INFECTION; LETHARGY; LEUKEMIA; LIBIDO DISORDER; LUNG EMBOLISM; MOOD DISORDER; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; SEDATION; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; STEM CELL TRANSPLANTATION; THROMBOEMBOLISM; THYROID DISEASE; TREATMENT OUTCOME; TREMOR; VEIN THROMBOSIS; VERTIGO; WALDENSTROEM MACROGLOBULINEMIA; XEROSTOMIA;

EID: 0038445682     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.7.1211     Document Type: Review

References (145)

1. MCBRIDE WG: Thalidomide and congenital abnormalities. Lancet (1961) 2:1358 (Letter).
2. D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082-4085.
3. ZWINGENBERGER K, WNENDT S: Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflamm. (1995) 46:177-211.
4. SINGHAL S, MEHTA J: Thalidomide in cancer. Biomed. Pharmacother. (2002) 56:4-12.
5. BRUERA E, NEUMANN CM, PITUSKIN E, CALDER K, BALL G, HANSON J: Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann. Oncol. (1999) 10:857-859.
6. MOEHLER T, NEBEN K, BENNER A et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 98:3846-3848.
7. NATHAN P, GORE M, EISEN T: Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma. J. Clin. Oncol. (2002) 20:1429-1430.
8. FIGG WD, RAJE S, BAUER KS et al.: Pharmacokinetics of thalidomide in an elderly prostate cancer population. J. Pharm. Sci. (1999) 88:121-125.
9. FINE HA, FIGG WD, JAECKLE K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. (2000) 18:708-715.
10. THOMAS DA, KANTARJIAN HM: The revitalization of thalidomide. Ann. Oncol. (2001) 12:885-886.
11. NG SSW, BROWN M, FIGG WD: Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed. Pharmacother. (2002) 56:194-199.
12. DECKERS M, VAN DER PLUIJM G, DOOIJEWAARD S et al.: Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. Lab. Invest. (2001) 81:5-15.
13. LENZ W: A short history of thalidomide embryopathy. Teratology (1988) 38:203-215.
14. BAUER KS, DIXON SC, FIGG WD: Inhibition of angiogenesis by thalidomide requires metabolic activation wich is species-dependent. Biochem. Pharmacol. (1998) 55:1827-1834.
15. STEPHENS T, FILLMORE B: Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology (2000) 61:189-195.
16. MINCHINTON AI, FRYER KH, WENDT KR, CLOW KA, HAYES MMM: The effect of thalidomide on experimental tumors and metastases. Anti-Cancer Drugs (1996) 7:339-343.
17. FUJITA J, MESTRE JR, ZELDIS JB, SUBBARAMAIAH K, DANNEMBERG AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. (2001) 7:3349-3355.
18. TSUJII M, KAWANO S, TSUJII S, SAWAOKA H, HORI M, DUBOIS RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93:705-716.
19. STOLINA M, SHARMA S, LIN Y et al.: Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by alterating the balance of IL-10 and IL-12 synthesis. J. Immunol. (2000) 164:361-370.
20. 2 in human colon cancer cells. Cancer Res. (1998) 58:362-366.
21. JOURDAN M, TARTE K, LEGOUFFE E et al.: Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine Netw. (1999) 10:65-70.
22. CARTER A, MERCHAV S, SILVIAN-DRAXLER I et al.: the role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol. (1990) 74:424-431.
23. MOREIRA A, SAMPAIO E, ZMUIDZINAS A, FINDT P, SMITH K, KAPLAN G: Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing mRNA degradation. J. Exp. Med. (1993) 177:1675-1680.
24. TURK B, JIANG H, LILU J: Binding of thalidomide to α1-acid- glycoprotein may be involved in its inhibition of tumor necrosis factor production. Proc. Natl. Acad. Sci. USA (1996) 93:7552-7556.
25. CHING L, BROWNE W, TCHERNEGOVSKI R: Interaction of thalidomide, phthalamide analogues of thalidomide and pentoxifylline with the antitumor agent 5,6-dimethylxanthenone-4-acetic acid: cocomitant reduction of serum tumor necrosis factor-alpha and enhancement of antitumor activity. Br. J. Cancer (1998) 78:336-343.
26. BALDWIN AS: The NF-κB and I-κB proteins: new discoveries and insights. Ann. Rev. Immunol. (1996) 14:649-683.
27. BALDWIN AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. (2001) 107:241-246.
28. KEIFER JA, GUTTRIDGE DC, ASHBURNER BP, BALDWIN AS: Inhibition of NF-κB activity by thalidomide trough suppression of I κB kinase activity. J. Biol. Chem. (2001) 276:22382-22387.
29. MOLLER DR, WYSOCKA M, GREENLEE BM et al.: Inhibition of IL-12 production by thalidomide. J. Immunol. (1997) 159:5157-5161.
30. MOREIRA AL, TSENOVA-BERKOVA L, WANG J et al.: Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle Lung Dis. (1997) 78:47-55.
31. ROWLAND TL, MCHUGH SM, DEIGHTON J, DEARMAN RJ, EWAN PW, KIMBER I: Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology (1998) 40:11-20.
32. HASLETT P, HEMPSTEAD M, SEIDMAN C et al.: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retrovir. (1997) 13:1047-1057.
33. SHANNON EJ, SANDOVAL F: Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology (1995) 31:109-116.
34. PARTIDA-SANCHEZ S, FAVILA-CASTILLO L, PEDRAZA-SANCHEZ S et al.: IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with Type II lepra reaction on thalidomide treatment. Int. Arch. Allergy Immunol. (1998) 116:60-66.
35. HASLETT PA, CORRAL LG, ALBERT M, KAPLAN G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. (1998) 187:1885-1892.
36. MARRIOTT JB, CLARKE IA, DREDGE K, MULLER G, STIRLING D, DALGLEISH A: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4+ and CD8+ T cells. Clin. Exp. Immunol. (2002) 130:75-84.
37. WALCHNER M, MEURER M, PLEWIG G, MESSER G: Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int. J. Dermatol. (2000) 39:383-388.
38. HALES B: Thalidomide on the comeback trail. Nat. Med. (1999) 5:489-490.
39. MARKS MG, SHI J, FRY MO et al.: Effects of putative hydroxylated metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol. Pharm. Bull. (2002) 25:597-604.
40. CORRAL LG, HASLETT PAJ, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. (1999)163:380-386.
41. RICHARDSON PG, SCHLOSSMAN R, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple mieloma. Blood (2002) 100:3063-3067.
42. MARRIOTT JB, CLARKE IA, CZAJIKA A et al.: A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with aletred expression of bcl-2 family proteins. Cancer Res. (2003) 63:593-599.
43. RAJKUMAR SV, WITZIG TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev. (2000) 26:351-362.
44. ATTAL M, HAROUSSEAU J-L: Standard therapy versus autologous transplantation in multiple myeloma. Hematol. Oncol. Clin. North Am. (1997) 11:133-146.
45. DRAK J, KAUFMANN H, URBAUER E et al.: The biology of multiple myeloma. Lancet (2000) 126:441-447.
46. TRICOT G: New insights into role of microenvironment in multiple myeloma. Lancet (2000) 355:248-250.
47. BELLAMY WT, RICHTER L, FRUTIGER Y et al.: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. (1999) 59:728-733.
48. PODAR K, TAI Y-T, DAVIES FE et al.: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood (2001) 98:428-435.
49. VACCA A, RIBATTI D, PRESTA M et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood (1999) 93:3064-3073.
50. HALLEK M, BERGSAGEL PL, ANDERSON KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 91:3-21.
51. TU Y, RENNER S, XU F et al.: BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. (1998) 58:256-262.
52. HUSSEIN MA: Non traditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist (2002) 7:20-29.
53. ZANGARI M, BARLOGIE B, PRATHER J et al.: Marked activity also in del 13 multiple myeloma of PS 341 and subsequent thalidomide in a setting of resistance to post-autotransplant salvage therapies. Blood (2002) 100:105a.
54. SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565-1571.
55. GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 31:213-221.
56. SAMPAIO EP, SARNO EN, GALILLY R et al.: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. (1991) 173:699-703.
57. MARRIOTT JB, MULLER G, DALGLEISH AG: Thalidomide as an emerging immunotherapeutic agent. Immunol. Today (1999) 20:538-540.
58. MCHUGH SM, RIFKIN IR, DEIGHTON J et al.: The immunosuppressive drug thalidomide induces T helper cell Type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. (1995) 99:160-167.
59. DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210-216.
60. BAIDAS SM, WINER EP, FLEMING GF et al.: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J. Clin. Oncol. (2000) 18:2710-2717.
61. EISEN T, BOSHOFF C, MAK I et al.: Continous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer (2000) 82:812-817.
62. DALIANI D: Development of angiogenesis inhibition as therapy for prostate cancer. Oncology (Huntingt.) (2000) 14:21-23.
63. YARCHOAN R: Therapy for Kaposi's sarcoma: recent advances and experimental approaches. J. Acquir. Immune Defic. Syndr. (1999) 21(Suppl. 1):S66-S73.
64. RAJKUMAR SV, FONSECA R, DISPENZIERI A et al.: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proc. (2000) 75:897-901.
65. BARLOGIE B, ZANGARI M, SPENCER T et al.: Thalidomide in the management of multiple myeloma. Semin. Hematol. (2001) 38:250-259.
66. RAJE N, ANDERSON K: Thalidomide - a revival story. N. Engl. J. Med. (1999) 341:1606-1609.
67. JULIUSSON G, CELSING F, MALM C et al.: Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol. (2000) 109:89-96.
68. KNELLER A, RAANANI P, BEN-BASSAT I et al.: Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br. J. Haematol. (2000) 108:391-393.
69. ALEXANIAN R, WEBER D, GIRALT S, DELASALLE K: Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann. Oncol. (2002) 13:1116-1119.
70. DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals Onc. (2001) 12:991-995.
71. WEBER D, RANKIN K, GAVINO M et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21:16-19.
72. MOEHLER TM, NEBEN K, BENNER A et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 98:3846-3848.
73. ZANGARI M, ANAISSIE E, BARLOGIE B et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 98:1614-1615.
74. GARCIA-SANZ I, GONZALEZ-FRAILE MI, SIERRA M, LOPEZ C, GONZALEZ M, SAN MIGUEL JF: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol. J. (2002) 3:43-48.
75. RICHARDSON PG, SCHLOSSMAN RL, HIDESHIMA T: A Phase I study of oral CC5013, an immunomodulatory thalidomide derivative in patients with relapsed and refractory multiple myeloma. Blood (2001) 98:775 (Abstract).
76. SELDIN DC, CHOUFANI EB, DEMBER LM et al.: Tolerability and efficacy of thalidomide for the teratment of patients with light chain-associated (AL) amyloidosis. Clin. Lymphoma (2003) 3:241-246.
77. DIMOPOULOS MA, ZOMAS A, VINIOU NA et al.: Treatment of Waldenstrom's macroglobulinemia with thalidomide. J. Clin. Oncol. (2001) 19:3596-3601.
78. TREON SP, AGUS TB, LINK B et al.: CD-20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J. Immunother. (2001) 24:272-279.
79. DESIKAN R, LI Z, JAGANNATH S: Waldenstrom's macroglobulinaemia: current therapy and future approaches. BioDrugs (2002) 6:201-207.
80. COLEMAN M, LEONARD J, LYONS L et al.: Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin. Oncol. (2003) 30:270-274.
81. RIBATTI D, VACCA A, NICO B, FANELLI M, RONCALI L, DAMMACCO F: Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur. J. Haematol. (1996) 56:45-53.
82. RIBATTI D, VACCA A, MARZULLO A, RIA R, RONCALI L, DAMMACCO F: Angiogenesis extent and density of mast cells with tryptase activity increase simultaneously with pathological progression in B-cell non Hodgkin's lymphomas. Int. J. Cancer (2000) 85:171-175.
83. VACCA A, RIBATTI D, RUCO L et al.: Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br. J. Cancer (1999) 79:965-970.
84. WILSON EA, JOPANPUTRA S, JACKSON R, PARKER AN, MCQUAKER IG: Response to thalidomide in chemotherapy-resistant mantle cell lymphoma. A case report. Br. J. Haematol. (2002) 119:128-130.
85. PADRO' T, RUIZ S, BIEKER R et al.: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood (2000) 95:2637-2644.
86. STEINS MB, PADRO T, BIEJER R et al.: Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood (2002) 99:834-839.
87. PRUNERI G, BERTOLINI F, SOLIGO D et al.: Angiogenesis in MDS. Br. J. Cancer (1999) 81:1398-1401.
88. RAZA A, MEYERP, DUTT D et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood (2001) 98:958-65.
89. STRUPP C, GERMING U, AIVADO M, MISGELD E, HAAS R, GATTERMANN N: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia (2002) 16:1-6.
90. RAZA A: Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. (2000) 50:229-235.
91. FINE HA: The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. (1994) 20:111-121.
92. TAKAHASHI J, FUKUMOTO M, IGORSHI K et al.: Correlations of bFGF expression levels with degree of malignancy and vascularity in human gliomas. J. Neurosurg. (1992) 76:792-798.
93. ZAGZAG D, MILLER D, SATO Y et al.: Immunohistochemical localization of bFGF in astrocytomas. Cancer Res. (1990) 50:7393-7398.
94. PLATE KH, BREIER G, WEICH HA et al.: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 359:845-848.
95. SHWEIKI D, ITIN A, SOFFER D et al.: Vascular endothelial growth factor induced by hypoxia-initiated angiogenesis. Nature (1992) 352:843-845.
96. BREM S, COTRAN R, FOLKMAN J: Tumour angiogenesis: A quantitative method for histologic grading. J. Natl. Cancer Inst. (1972) 48:347-356.
97. MILLAUER B, SHAWVER LK, PLATE KH et al.: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 367:576-579.
98. MAXWELL M, NABER SP, WOLFE HJ et al.: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J. Clin. Invest. (1990) 86:131-140.
99. HSU SC, VOLPERT OV, STECK PA et al.: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin. Cancer Res. (1996) 56:5684-5691.
100. SHORT SC, TRAISH D, DOWE A et al.: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J. Neuroonc. (2001) 51:41-45.
101. MARX GM, PAVLAKIS N, MCCOWATT S et al.: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neuroonc. (2001) 54:31-38.
102. GASPARINI G, MORABITO A, MAGNANI E, GATTUSO D, CAPACCETTI B, ALBERTI AM: Thalidomide: an old sedative-hypnotic with anticancer activity? Curr. Opinion Invest. Drugs (2001) 2(9):1302-1308.
103. HOUGHTON AN, BLOOMER WD, CHU D et al.: NCCN practice guidelines for melanoma: the complete library of NCCN guidelines (CD-ROM). Version 2000. National Comprehensive Cancer Network, Rockledge, PA, USA (2000).
104. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon α-2b. J. Clin. Oncol. (1999) 17:968-975.
105. DORRAL T, NEIGRIER S, CHEVREAN C et al.: Randomized trial of treatment with cisplatin, and interleukin-2 either alone or in combination with interferon α-2a in patients with metastatic melanoma. Cancer (1999) 85:1060-1066.
106. MIDDLETON MR, GROB JJ, AARONSON N et al.: Randomized Phase III study of temozolamide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. (2000) 18:158-166.
107. ARANCE A, MIDDLETON M, LORIGAN PC et al.: Three-arm Phase II study of temozolamide (TMZ) in metastatic melanoma (MM): preliminary results. Proc. Am. Soc. Clin. Oncol. (2000) 19:573a (Abstract 2257).
108. AHMED M, READY N, ARONSON F et al.: Phase II study of outpatient biochemotherapy with temozolamide, for metastatic melanoma: BRUOG MEL 69. Proc. Am. Soc. Clin. Oncol. (2001) 20:287b (Abstract 2900).
109. ATKINS MB, GOLLOB JA, MIER JW et al.: Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolamide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol. (2001) 20:349a (Abstract 1391).
110. BLEECHEN NM, NEWLANDS ES, LEE SM et al.: Cancer Research campaign Phase II trial of temozolamide in metastatic melanoma. J. Clin. Oncol. (1995) 13:910-913.
111. BROCK CS, NEWLANDS ES, WEDGE SR et al.: Phase I trial of temozolamide using an extended continuous oral schedule. Cancer Res. (1998) 58:4363-4367.
112. HWU WJ, KROWN SE, PANAGEAS KS et al.: Temozolamide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J. Clin. Oncol. (2002) 20:2610-2615.
113. FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat. Med. (1995) 1:27-31.
114. TEICHER BA, HOLDEN SA, GULSHAN A et al.: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int. J. Cancer (1994) 57:920-925.
115. MOTZER RJ, BANDER NH, NANUS DM et al.: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335:865-875.
116. NANUS DM, SCHMITZ-DRAGER BJ, MOTZER RJ: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J. Natl. Cancer Inst. (1993) 85:1597-1579.
117. NATHAN PD, EISEN G: The biological treatment of renal cell carcinoma and melanoma. Lancet Oncol. (2002) 3:89-96.
118. MIZUTANI Y, CHAUHAN D, SHIMA Y et al.: Over coming TNF-α and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha prodrugs: the role of TNF-α downregulation in tumor cell sensitisation. J. Urol. (1994) 151:1697-1702.
119. ESCUDIER B, LASSAU N, COUANET D et al.: Phase II trial of thalidomide in renal cell carcinoma. Ann. Oncol. (2002) 13(7):1029-1035.
120. DESAI AA, VOGELZANG NJ, RINI BI et al.: A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer (2002) 95(8):1629-1636.
121. STEBBING J, BENSON C, EISEN Y et al.: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer (2001) 85(7):953-958.
122. MOTZER RJ, BERG W, GINSBERG et al.: Phase II trial of Thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. (2002) 20(1):302-306.
123. DALIANI DD, PAPANDREOU CN, THALL PF et al.: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer (2002) 95(4):758-765.
124. MINOR DR, MONROE D, DAMICO LA et al.: A Phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest. New Drugs (2002) 20(4):389-393.
125. MOTZER RJ, MAZUMDAR M, BACIK J et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. (1999) 17:2530-2540.
126. TRAVIS WD, COLBY TV, CORRIN B: World Health Organization Classification of Lung and Pleural Tumors (3rd Edn). Springer-Verlag, Berlin (1999).
127. CARNEY DN: Lung cancer - time to move on from chemotherapy. N. Engl. J. Med. (2002) 346:126-128.
128. BROKER LE, GIACCONE G: The role of new agents in the treatment of non-small cell lung cancer. Eur. J. Cancer (2002) 38:23476-23461.
129. MERCHANT JJ, HAMMES LC, LARSON ML et al.: Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 19(Abstract No. 2130).
130. SCHNEIDER J, WNENDT S, KORIOTH J et al.: Thalidomide inhibits superantigen-induced TNFα release in mice. 12th European Immunology Meeting of the European Federation of Immunologic Societies, Barcelona, Spain (1994).
131. KELLY K: New chemotherapeutic agents for small cell lung cancer. Chest (2000) 117(Suppl. 4):156S-162S.
132. MALL JW, PHILIPP AW, MALL W et al.: Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy. Angiogenesis (2002) 5:11-13.
133. FIFE K, HOWARD MR, GRACIE F et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int. J. STD AIDS (1998) 9:751-755.
134. LITTLE RF, WYVILL KM, PLUDA JM et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (2000) 18:2593-602.
135. GOVINDARAJAN R, HEATON KM, BROADWATER R et al.: Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet (2000) 356:566-567.
136. FIGG WD, DAHUT W, DURAY P et al.: A randomised Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. (2001) 7:1888-1893.
137. MCNAMARA MJ, ALEXANDER HR, NORTON JA: Cytokines and their role in the pathophysiology of cancer cachexia. J. Parenter. Enteral. Nutr. (1992) 16:50S-55S.
138. BOASBERG PD, O'DAY SJ, WEISBERG M et al.: Thalidomide induced cessation of weight loss and improved advanced cancer patients with cachexia. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 2396).
139. ZELDIS JB, WILLIAMS BA, THOMAS SD, ELSAYED ME: S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. (1999) 21:310-330.
140. HARLAND CC, STEVENTON GB, MARSDEN JR: Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur. J. Clin. Pharmacol. (1995) 49:1-16.
141. RAJKUMAR SV, GERTZ MA, WITZIG TE: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N. Engl. J. Med. (2000) 343:972-973.
142. FLAGEUL B, WALLACH D, CAVELIER-BALLOY B, BACHELEZ H, CARSUZAA F, DUBERTRET L: Thalidomide and thrombosis. Ann. Dermatol. Venereol. (2000) 127:171-174.
143. OSMAN K, COMENZO R, RAJKUMAR SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med. (2001) 344:1951-1952.
144. ZANGARI M, SIEGEL E, ANASSIE E et al.: risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (Pts) treated with thalidomide (Thal). Blood (2001) 98 (Abstract 681).
145. HUSSEIN MA: Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. Oncology (2000) 14:9-15.